Please find attached unaudited FS as of June 26

TEJNAKSH HEALTHCARE LIMITED Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves-Road, Pratap Nagar, Mumbai, Maharashtra - 400060 Head Office : Institute of Urology Sakri Raod, Dhule - 424001 CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995 Date: 13-08-2026 BSE Limited " Phiroze Jeejeebhoy Towers, Dalal Street, - Mumbai — 400 001 : Defir Sir/Madam, Scrip Code: 539428 Sub: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30 June, 2026. Please find the enclosed herewith Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended on 30" June, 2026 along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on Thursday, 13% August, 2026 at Shop No 1 Building Name: Shivprasad Harihar Singh Compound, Block Sector: Jogeshwari East, Road: Caves Road. Pratap Nagar -Mumbai, Maharashtra, 400060 at 3:00 pm., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is for your information and record. Thanking you. For :iZsh Healthcare Limited NS\oalt Dr. Ashish V. Rawandale "é Managing Director ’ 2 . DIN: - 02005733 * Maheshwari & Co. Chartered Accountants Independent Auditor’s Review Report on Unaudited Standalone Financial Results of Tejnaksh Healthcare Limited for the Quarter ended June 30, 2026 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Review Report to, The Board of Directors Tejnaksh Healthcare Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results of Tejnaksh Healthcare Limited (‘hereinafter referred to as ‘the Company’) for the quarter ended June 30, 2026 (the ‘Statement’), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations) 2. This Statement which is the responsibility of the Company's Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 (‘the Act) as amended, read with relevant rules issued thereunder (‘Ind AS 34) and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor oft he Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Attention is drawn to the fact that the figures for the three months ended March 31, 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end oft he third quarter of previous financial year had only been reviewed and not subjected to audit 5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Maheshwari & Co. Chartered Accountants Firm’s Registration-No.: 105834W Membegrship No.: 172133 UDIN:26172133GMUTTI9461 Place: Mumbai Date: August 13, 2026 Office: 1302/1303, Solaris One, Vijay Nagar, Opp. Teli Gali, Andheri (East), 400069 Head office: 10-11, Third Floor, Esplanade Building, 3 A K Naik Marg, Near New Empire Cinema, Fort, CST, Mumbai 400 001 Tel.: +91-22-22077472/22072620, E-mail: vkasawa@maheshwariandco.in, Website: www.maheshwariandco.in TEJNAKSH HEALTHCARE LIMITED Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060 Head Office : Institute of Urology Sakri Raod, Dhule - 424001 CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995 TEJNAKSH HEALTHCARE LIMITED (CIN: L85100MH2008PLC179034) Statement of Standalone Financial Results for quarter ended June 30,2026 All amounts are in Indian Rupees lakhs Cost of Materials Consuried o 020 435 0.07 479 CPu hr ac nh ga es se s In o If n s vt eno tc ok r- ii en s- ot f r ia nde i shed Goods§ , WorL l-n- 0 13.99 ¥ ; To1194 11.89 43.69 P Er mo pg lr oe ys es ea bn ed eS ft io tc sk - eI xn p- eT nr sa ed e * 5 1( 42 .A 0 68 9) B 16 57 .& 48 5) ( 15 8. 4 44 00 7) . 7i 7.X 69 DF ei pn ra en cc ie a c to is ot ns and amortization expense 31 21 59 8 30 3. 06 88 34 23 83 1 - 11 33 11 37 2 Other éxpenses 87.66 76.58 79.24 308.99 Total Expenses 148.23 130.29 141.41 576.58 Profit before Exceptional Items & Tax 45.10 61.55 45.07 178.56 Exceptional Items & g B Profit/ (Loss) Before Tax . 45.10 61.55 45.07 178.56 Tax expense: Current tax 1182 22.03 751 . 4319 Deferred tax 417 (10.89) 384 . (261) Profit /(Loss) for the period/year 29.11 50.41 33.73 137.98 Other Comprehensive Income/(Loss) Items that will not be reclassified to profit or loss : Remeasurement of defined employee benefit plans (0.13) . (005 034 098 Income tax effect on above 0.03 001 (0.09) (025) Total Other Comprehensive income for the year, net of tax (0.10) (0.04) 025 073 Total Comprehensive Income (Net of Tax) for the Period/Year . 29.01 50.37 33.98 13871 Paid Up Equity Share Capital (face value 5/- each) 1,015.68 1,015.68 1,015.68 1,015.68 Reserves and surplus during the period . . 166387 Earnings per share (EPS) Basic and Diluted Earing Per Share 014 039 017 068 Not Annualized Yearly TEJNAKSH HEALTHCARE LIMITED Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060 Head Office : Institute of Urology Sakri Raod, Dhule - 424001 CIN : L85100MH2008PLC179034, E-mail : Instituteofurology@gmail.com Website : www.tejnaksh.com | Tel. No. 022-27454 2311, 02562 - 245322 / 245995 Notes to the Standalone Financial Results for the period ended June 30, 2026 1. The above standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 13, 2026. The - Statutory Auditors have carried out limited review of the unaudited standalone interim financial results for the quarter ended June 30, 2026 and have issued an unmodified conclusion on the same. 2. The above standalone financial results have b [Showing first 8,000 characters — download PDF for full document]